Bioimpact Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bioimpact capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bioimpact Capital Today - Breaking & Trending Today

Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at StockNews.com

StockNews.com cut shares of Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) from a hold rating to a sell rating in a report released on Thursday morning. A number of other research analysts have also issued reports on IOVA. Wells Fargo & Company upgraded Iovance Biotherapeutics from an equal weight rating to an overweight rating and increased […] ....

Stifel Nicolaus , Iovance Biotherapeutics , Robertw Baird , Iovance Biotherapeutics Company Profile , Ensign Peak Advisors Inc , Iovance Biotherapeutics Inc , Wells Fargo Company , Bioimpact Capital , Cubist Systematic Strategies , Get Rating , Chardan Capital , Moderate Buy , Systematic Strategies , Peak Advisors Inc , Nasdaq Iova , Stocknews Com ,

Reunion Neuroscience : NOTICE OF SPECIAL MEETING OF SHAREHOLDERS - Form 6-K

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS

TO BE HELD ON JULY 12, 2023

AND

MANAGEMENT INFORMATION CIRCULAR

JUNE 13, 2023

. | June 20, 2023 ....

District Of Columbia , United States , Prince Edward Island , Province Of Ontario , United Kingdom , Fred Grossman , Mujeeb Jafferi , Nathan Bryson , Hannah Young , Wilmer Cutler Pickering Hale , Helen Boudreau , Barry Fishman , Williama Bortolin , Ansbert Gadicke , Robert Alexander , Aaron Sonshine , Curtis Weber , Ryan Yermus , Hannan Fleiman , Kevin Boyer , Bennett Jones , Alan Gardner , Greg Mayes , Jessica Kimmel , Ruixiu Li , Ellen Lubman ,

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Moderate Buy" from Analysts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) has earned an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers […] ....

Stifel Nicolaus , Iovance Biotherapeutics , Strategic Wealth Advisors Group , Iovance Biotherapeutics Company Profile , Wells Fargo Company , Cubist Systematic Strategies , Iovance Biotherapeutics Inc , Bioimpact Capital , Get Rating , Systematic Strategies , Montreal Can , Wealth Advisors Group , Nasdaq Iova ,

Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $38.63 Consensus Price Target from Analysts

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. […] ....

William Blair , Bioimpact Capital , Verve Therapeutics Inc , Nikko Asset Management Americas Inc , Canaccord Genuity Group , Cheyne Capital Management United Kingdom , Ci Investments Inc , Verve Therapeutics , Get Rating , Genuity Group , Therapeutics Trading Down , Asset Management Americas , Verve Therapeutics Daily , Nasdaq Verv ,

683 Capital Management LLC Decreases Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

683 Capital Management LLC lessened its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) by 41.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,000,000 shares of the biotechnology company’s stock after selling 705,000 shares during the period. 683 Capital Management LLC […] ....

Iovance Biotherapeutics , Stifel Nicolaus , Capital Management , Wells Fargo Company , Strategic Wealth Advisors Group , Iovance Biotherapeutics Company Profile , Iovance Biotherapeutics Inc , Bioimpact Capital , Cubist Systematic Strategies , Get Rating , Systematic Strategies , Montreal Can , Wealth Advisors Group ,